Business
Masimo to be Acquired by Danaher for $180.00 Per Share
Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global medical innovator, t...
About this update from Discovery Harbour Resources Corp.
[{"type":"text","content":"Masimo to be Acquired by Danaher for $180.00 Per Share\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) (“Danaher”) will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the “Transaction”).\n \n\n The Transaction has been unanimously approved by both Masimo’s Board of Directors and Danaher’s Board of Directors. Masimo will become a standalone business unit and brand within Danaher’s Diagnostics segment and will operate autonomously while strengthening Danaher’s offering in acute care settings.\n \n\n Katie Szyman, Chief Executive Officer of Masimo, stated: “We look forward to joining Danaher and continuing our growth and momentum as the global leader in patient monitoring. Danaher shares our commitment to investing in talent and innovation and will be an ideal fit to help power the next chapter of Masimo. Importantly, becoming part of Danaher’s Diagnostics segment will strengthen our ability to scale our monitoring technologies globally and accelerate our mission of delivering Masimo innovations that empower clinicians to transform patient care.”\n \n\n Michelle Brennan, Chairman of Masimo’s Board of Directors, stated: “This transaction represents a unique opportunity to deliver certain and premium value for Masimo’s shareholders, enhance outcomes for customers and patients, and provide compelling career growth paths for our employees across the world. The Board evaluated a broad range of opportunities over the past several months – which included pursuing our standalone strategy – and engaged with multiple other potential partners. Ultimately, it became evident that this transaction with Danaher was the most value-enhancing path for Masimo and all its stakeholders.”\n \n\n The Transaction is subject to the satisfaction or waiver of certain closing conditions, including the receipt of required regulatory approvals. It is expected to close in the second half of 2026.\n \n\n Masimo will report its fourth quarter and full-year 2025...